acromegalic

Also found in: Thesaurus, Medical, Encyclopedia, Wikipedia.

Related to acromegalic: acromegalic gigantism

ac·ro·meg·a·ly

(ăk′rō-mĕg′ə-lē)

A chronic disorder caused by overproduction of human growth hormone usually by the pituitary gland, characterized by enlargement of the bones of the extremities and the skull and often by the development of complications such as diabetes, hypertension, and osteoarthritis.

[French acromégalie : Greek akron, top, extremity (from neuter of akros, extreme; see acro-) + Greek megas, megal-, big; see meg- in Indo-European roots.]

ac′ro·me·gal′ic (-mĭ-găl′ĭk) adj. & n.

American Heritage® Dictionary of the English Language, Fifth Edition. Copyright © 2016 by Houghton Mifflin Harcourt Publishing Company. Published by Houghton Mifflin Harcourt Publishing Company. All rights reserved.

ThesaurusAntonymsRelated WordsSynonymsLegend:

Switch to new thesaurus

Adj.

acromegalic - marked or affected by enlargement or hypertrophy of the extremities or the face; "a protruding acromegalic jaw"

unshapely - not well-proportioned and pleasing in shape; "a stout unshapely woman"

Mentioned in ?

References in periodicals archive ?

Predicting difficult laryngoscopy in acromegalic patients undergoing surgery for excision of pituitary tumors: a comparison of extended Mallampati score with modified Mallampati classification.

Elektif Non-Kardiyak Cerrahi Gecirecek Eri[thorn]kinlerin Pre-Operatif Degerlendirme Kilavuzu: Avrupa Anesteziyoloji Dernegi'nden Guncellenmis Onerilerin Ozeti/Pre-Operative Evaluation of Adults Undergoing Elective Noncardiac Surgery: Summary of the Updated Guideline From the European Society of Anaesthesiology

After non-effective pituitary surgery, somatostatin receptor ligand (octreotide LAR) and/or dopamine agonist (cabergoline) were used in acromegalic patients to achieve hormonal and/or tumor control.

Study of major genetic factors involved in pituitary tumorigenesis and their impact on clinical and biological characteristics of sporadic somatotropinomas and non-functioning pituitary adenomas

Cure rate after endoscopic surgery was 50% in acromegalic patients.17 For secretory adenomas D'Haens et al.18 reported an increased cure rate (50%-65%) with endoscopic removal.

Endoscopic Trans-Sphenoidal surgery: Efficacy and response in pituitary adenoma

Other complaints were decreased level of consciousness, decreased vision, vomiting, hearing loss, acromegalic features, numbness, proptosis, cerebrospinal fluid (CSF) rhinorrhoea, altered behaviour, ataxia, blindness, dysphagia, oculomotor nerve palsy, diplopia, vertigo, monoplegia, post-auricular discharge and tinnitus.

Short term outcomes following surgery in brain tumours sans neuronavigation

Oner et al., "Complete surgical resolution of bilateral total opthalmoplegia without visual field defect in an acromegalic patient presented with pituitary apoplexy," Endocrine Journal, vol.

Pituitary Apoplexy Presenting as Ophthalmoplegia and Altered Level of Consciousness without Headache

Chanson et al., "Slow release lanreotide treatment in acromegalic patients previously normalized by octreotide," The Journal of Clinical Endocrinology & Metabolism, vol.

Impact of Long-Acting Somatostatin Analogues on Glucose Metabolism in Acromegaly: A Hospital-Based Study

An SSTR5 mutation in tumor tissue was reported in one acromegalic patient who was resistant to SST analog treatment, which implies a role for SSTR5 in predicting response.[sup][29] SSTR5 expression on the top of SSTR2 reportedly may account for long-term suppression of hormone hypersecretion [sup][24] and tumor growth.[sup][30] Additional studies with a larger number of cases are necessary to establish the exact role of SSTR5 in OCT therapy for TSHoma.

Short-term Preoperative Octreotide for Thyrotropin-secreting Pituitary Adenoma

Early postoperative indicators of late outcome in acromegalic patients.

Decrease of Serum IGF-I following Transsphenoidal Pituitary Surgery for Acromegaly

[14] showed that significant increase in GH level in acromegalic patients group compared to control group.

Total antioxidant activity and insulin resistance in Iraqi male patients with active Acromegaly: a case control study

Control of tumor size and disease activity during cotreatment with octreotide and the growth hormone receptor antagonist pegvisomant in an acromegalic patient.

Preparation and characterization of an antibody antagonist that targets the porcine growth hormone receptor

The aim of this study was to investigate association between the frequencies of LEP and LEPR gene polymorphisms and subclinical atherosclerosis in acromegalic patients.

Leptin receptor gene polymorphism may affect subclinical atherosclerosis in patients with acromegaly

Acromegalic patients have a deficient activation of brain areas associated with memory, in this case, the temporal and prefrontal region.